{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', \"In the event that a subject's e-diary becomes nonfunctional or is otherwise not available for data\", 'recording, a paper diary may be utilized for short-term angioedema event and dose recording', 'until the subject receives a replacement e-diary. Other scenarios for which the use of the paper', 'diary and/or the shipment of a replacement e-diary may be permitted, following consultation', 'with the sponsor. During the period of paper diary use, it will be necessary for the subject to', 'contact the investigator after each angioedema event that occurs.', 'Subjects who discontinue study drug should continue to record the occurrence of angioedema', 'events in their e-diary until the follow-up visit.', '11.4.1.', 'Screening and Parts 1 and 2', '11.4.1.1.', 'Investigator Follow-up of Angioedema Events and Expert Confirmation of', 'Angioedema Events', 'Sites will have real-time access to e-diary entries for their subjects, including all angioedema', 'event details recorded, and will receive a notification for each angioedema event that is recorded.', 'For all angioedema events that are recorded from screening through the end of Part 2, the', 'investigator (or appropriately-trained designee) will review the e-diary record of the angioedema', 'event details. Subjects will then be contacted within approximately 2 business days of the end of', 'the angioedema event to discuss the clinical characteristics of the angioedema event and any', 'questions the investigator has on the entered data, or to gain additional angioedema event details', 'not included in the e-diary that the investigator deems important to clinically evaluate the event,', 'as applicable. The investigator-collected information, in conjunction with the e-diary record, will', 'be used by an independent expert to verify or reject each event recorded in the e-diary as a', 'confirmed angioedema event.', 'The investigator e-diary data review and subject contact summaries will be documented in the', 'source records and made available to an independent expert for their verification (confirmation', 'or rejection) of the event.', 'During the run-in period of 56 days beginning at the screening visit, angioedema events used to', 'establish eligibility must meet the following stipulations, in addition to expert confirmation that', 'the recorded event is an angioedema event:', 'The angioedema events are unique, which is defined as an angioedema event that', 'does not begin within 48 hours of the end of a previous angioedema event.', 'The angioedema events must have either been treated, required medical attention, or', 'be documented to cause functional impairment based on subject entry in the e-diary.', 'Functional impairment is defined as the subject being unable to perform his or her', 'daily activities without restriction (ie, subject records that he or she is at least slightly', 'restricted in daily activities during the angioedema event).', 'The angioedema events must include symptoms of swelling. The expert will consider', 'that symptoms of swelling, in addition to visible swelling, may also include', 'symptoms in the oropharyngeal or abdominal regions that are indicative of internal', 'swelling.', '81']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'During the entire screening period (run-in period and the period after eligibility has been', 'established during the run-in period but prior to randomization), angioedema events must meet', 'the following stipulations to be counted in the baseline angioedema event rate calculation', 'necessary for stratification, in addition to the expert confirmation:', 'The angioedema events are unique, which is defined as an angioedema event that', 'does not begin within 48 hours of the end of a previous angioedema event.', 'The angioedema event must have either been treated, required medical attention, or', 'be documented to cause functional impairment based on subject entry in the e-diary.', 'Functional impairment is defined as the subject being unable to perform his or her', 'daily activities without restriction (ie, subject records that he or she is at least slightly', 'restricted in his or her daily activities during the angioedema event).', 'The angioedema events must include symptoms of swelling. The expert will consider', 'that symptoms of swelling, in addition to visible swelling, may also include', 'symptoms in the oropharyngeal or abdominal regions that are indicative of internal', 'swelling.', 'After randomization through the end of Part 2, the expert will use their judgment to confirm or', 'reject a reported event as an angioedema event; however, all angioedema events must include', 'symptoms of swelling. The expert will consider that symptoms of swelling, in addition to visible', 'swelling, may also include symptoms in the oropharyngeal or abdominal regions that are', 'indicative of internal swelling.', 'The selection of the independent expert(s) who will confirm or reject attacks will be made by the', 'sponsor and may or may not be an investigator in the current study. Expert expectations for', 'turn-around times of the event confirmation or rejection and how the event confirmation or', 'rejection will be received by the investigator and site staff, especially in the period between', 'screening and baseline, will be communicated separately.', '11.4.1.2. Scheduled Telephone Contact', 'The investigator (or designee) must call and talk to the subject once weekly during Part 1 and', 'during Part 2 at Weeks 40 and 44. Alternative forms of interactive communication such as', 'returned email and cellular text correspondence are acceptable. During all calls, the investigator', \"(or designee) will assess the subject's overall wellbeing, discuss compliance (if applicable),\", 'proper recording of angioedema event details (if applicable), or any usability issues with the', 'e-diary. The phone call may be omitted if the subject records an angioedema event, as the', 'investigator must call and confirm or reject the angioedema event.', '11.4.2.', 'Part 3', '11.4.2.1. Confirmation of Angioedema Events', 'Subjects will continue to document all angioedema events that occur in their e-diary throughout', 'Part 3. Investigator follow-up of angioedema events and expert confirmation of events will not', 'be required for Part 3. All angioedema events recorded by the subjects will be reviewed and', 'confirmed or rejected according to a set of pre-defined rules prior to inclusion in effectiveness', 'analyses. These rules will be outlined in the SAP.', '82']\n\n###\n\n", "completion": "END"}